Trial reportFrontiers in pharmacology2025
Prophylactic effect of the traditional Chinese medicine formula
Trial report in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05289726 (Randomized Controlled Clinical Trials to Evaluate the Preventive Effect of Traditional Chinese Medicine TDX105 on Anti-tumor Target Therapy Regorafenib Induced Dermatologic Toxicities), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Clinical Trials to Evaluate the Preventive Effect of Traditional Chinese Medicine TDX105 on Anti-tumor Target Therapy Regorafenib Induced Dermatologic Toxicities
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hand-foot skin reaction (HFSR) is the most common side effect of the antineoplastic drug Regorafenib. It severely affects patients' quality of life, and no clear treatment is currently available for the condition. In preliminary clinical studies, the traditional Chinese medicine compound Danxiong Granules (TDX105) has shown significant therapeutic benefit for HFSR. This study aimed to evaluate the prophylactic effect of TDX105 for HFSR. Methods: A total of 137 colorectal cancer patients scheduled for Regorafenib treatment were randomly assigned in a 2:1 ratio to a treatment group (n = 91) and a control group (n = 46), which received basic treatment (topical urea ointment) plus TDX105 or placebo, respectively, for 8 weeks. Follow-up was conducted until tumor regression or Regorafenib discontinuation. The primary study endpoint was the incidence of HFSR within 8 weeks. Results: The total incidence of HFSR was markedly lower in the treatment group than in the control group (76.1% vs. 53.8%), particularly for grade 3 HFSR (7.7% vs. 19.6%, Conclusion: TDX105 significantly reduced the incidence and severity of Regorafenib-induced HFSR. This finding lends support to the use of TDX105 for prevention of HFSR. Clinical trial registration: NCT05289726.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.